Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 2/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.48 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757556 | 0.87 | CHRNB4 (0.47) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL30375430 | 0.86 | LTA4H (0.51) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL30376216 | 0.85 | MAOB (0.47) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL29275168 | 0.84 | MEN1 (0.53) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL30375153 | 0.83 | IMPDH2 (0.56) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL31757537 | 0.82 | CHRNA7 (0.53) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL31757553 | 0.82 | APP (0.45) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL31757558 | 0.82 | APP (0.45) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL30233681 | 0.82 | MAOA (0.51) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL30375571 | 0.81 | CYP17A1 (0.58) | CHRNB4CHRNA3CHRNA7CHRNA10CHRNA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | CHRNB4 538/4885CHRNA3 626/4885CHRNA7 568/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | CHRNB4 2082/4885CHRNA3 2606/4885CHRNA7 1582/4885 |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CHRNB4 2082/4885CHRNA3 2606/4885CHRNA7 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.